Antibiotic Consumption 2017-2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic

Our aim was to determine the impact of antimicrobial stewardship tools (ASTs) and the COVID-19 pandemic on antibiotic consumption (AC). We used the national software Consores<sup>®</sup> to determine AC in DDD/1000 days of hospitalization from 2017 to 2022 in voluntary private hospitals...

Full description

Saved in:
Bibliographic Details
Main Authors: Pierre-Marie Roger (Author), Diane Lesselingue (Author), Anouk Gérard (Author), Jacques Roghi (Author), Pauline Quint (Author), Sophie Un (Author), Agnès Chincholle (Author), Assi Assi (Author), Odile Bouchard (Author), Véronique Javaudin (Author), Eric Denes (Author)
Format: Book
Published: MDPI AG, 2024-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_6d0b6296c44a45d58a1333dc72a99b9c
042 |a dc 
100 1 0 |a Pierre-Marie Roger  |e author 
700 1 0 |a Diane Lesselingue  |e author 
700 1 0 |a Anouk Gérard  |e author 
700 1 0 |a Jacques Roghi  |e author 
700 1 0 |a Pauline Quint  |e author 
700 1 0 |a Sophie Un  |e author 
700 1 0 |a Agnès Chincholle  |e author 
700 1 0 |a Assi Assi  |e author 
700 1 0 |a Odile Bouchard  |e author 
700 1 0 |a Véronique Javaudin  |e author 
700 1 0 |a Eric Denes  |e author 
245 0 0 |a Antibiotic Consumption 2017-2022 in 30 Private Hospitals in France: Impact of Antimicrobial Stewardship Tools and COVID-19 Pandemic 
260 |b MDPI AG,   |c 2024-02-01T00:00:00Z. 
500 |a 10.3390/antibiotics13020180 
500 |a 2079-6382 
520 |a Our aim was to determine the impact of antimicrobial stewardship tools (ASTs) and the COVID-19 pandemic on antibiotic consumption (AC). We used the national software Consores<sup>®</sup> to determine AC in DDD/1000 days of hospitalization from 2017 to 2022 in voluntary private hospitals in France. The ASTs considered were: 1. internal guidelines; 2. the list of antibiotics with restricted access; 3. the presence of an antibiotic referent or 4. an ID specialist; and 5. proof of an annual meeting on antimicrobial resistance. Institutions with dedicated units for COVID-19 patients were specified. In 30 institutions, the total AC varied from (means) 390 to 405 DDD/1000 DH from 2017 to 2022. Fluoroquinolones and amoxicillin/clavulanate consumption decreased from 50 to 36 (<i>p</i> = 0.003) and from 112 to 77 (<i>p</i> = 0.025), respectively, but consumption of piperacillin/tazobactam increased from 9 to 21 (<i>p</i> < 0.001). Over the study period, 10 institutions with ≤2 AST had lower AC compared to 20 institutions with ≥3 AST (<i>p</i> < 0.01). COVID-19 units opened in 10 institutions were associated with a trend toward higher macrolide consumption from 15 to 25 from 2017 to 2020 (<i>p</i> = 0.065) and with an acceleration of piperacillin/tazobactam consumption from 2020 to 2022 (<i>p</i> ≤ 0.003). Antibiotic consumption in 30 private hospitals in France was inversely related to the number of AST. The COVID-19 pandemic was associated with limited impact on AC, but special attention should be paid to piperacillin/tazobactam consumption. 
546 |a EN 
690 |a antibiotic consumption 
690 |a defined daily doses 
690 |a antimicrobial stewardship 
690 |a tools 
690 |a COVID-19 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 13, Iss 2, p 180 (2024) 
787 0 |n https://www.mdpi.com/2079-6382/13/2/180 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/6d0b6296c44a45d58a1333dc72a99b9c  |z Connect to this object online.